Side-by-side · Research reference

CrystagenvsHexarelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BPhase 1HUMAN-REVIEWED19/45 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

Hexarelin

Hexapeptide GHRP · Cardio-tropic

100–200 mcgPer doseSmith 1996

Phase 1Evidence levelGhigo 1997

~70 minHalf-lifeSemenistaya 2010

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Crystagen

Hexarelin

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996 Ghigo 1997

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

Yes initially; tachyphylaxis with chronic useGhigo 1997

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

Hexarelin

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

100–200 mcg per injectionSmith 1996

Evidence basis

Animal / mechanistic

Phase 1 / Phase 2 trialsSmith 1996 Ghigo 1997

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

1–2× per day max (tachyphylaxis with chronic 3× daily)

Duration

Unknown — chronic administration presumed in animal models

4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)

Half-life

Not reported

~70 minSemenistaya 2010

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

04Side Effects & Safety

Parameter

Crystagen

Hexarelin

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Cortisol elevation

—

Modest at high dosesGhigo 1997

Prolactin elevation

—

Modest at high dosesGhigo 1997

Hunger

—

Strong appetite increase via ghrelin agonism

Tachyphylaxis

—

Receptor desensitisation with chronic dosingGhigo 1997

Cardiac effects

—

Direct cardio-tropic; potential benefit in MI but unstudied in humansGhigo 1997

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

Hexarelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

Hexarelin

·Untreated diabetes
·Severe hyperprolactinemia

05Administration Protocol

Parameter

Crystagen

Hexarelin

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen or thigh. Rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

Hexarelin

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

Hexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.

Hexarelin: 100 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Maximum GH pulse amplitude (with side-effect signal)

Smith 1996 Teichman 2006